根据美国食品药品管理局（FDA）发布的安全警告，患有无肝硬化的原发性胆汁性胆管炎（PBC）的患者使用Ocaliva® （奥贝胆酸）治疗时报告了严重的肝损伤。 Ocaliva 是一种法呢醇 X 受体激动剂，于 2016 年获得加速批准用于治疗 PBC。2021年，Ocaliva 的处方信息进行了更新，限制其仅用于某些患者，因为有报道称，患有代偿性或失代偿性肝硬化的 PBC ...

为探究 UDCA 对肥胖、高血压等慢性疾病的影响，相关研究人员开展关于 UDCA 对人体测量指标、血压和炎症影响的研究，发现其可改善 BMI 和 DBP，但会升高 SBP。该研究为临床治疗提供参考，推荐科研读者阅读。 在当今社会，肥胖、高血压和代谢综合征等慢性疾病 ...

A new study finds that ursodeoxycholic acid (UDCA) effectively dissolves gallstones in 60% of patients after sleeve ...

UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

为探究熊去氧胆酸（UDCA）对腹腔镜袖状胃切除术（LSG）后胆结石的治疗效果，研究发现 UDCA 有效，意义重大。 # 腹腔镜袖状胃切除术后胆结石治疗新突破：熊去氧胆酸的疗效研究 在当今社会，肥胖问题愈发严重，腹腔镜袖状胃切除术（LSG）作为一种广泛应用的 ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

Hepatocellular DILI is characterized by inflammation, necrosis, and apoptosis, while cholestatic DILI involves bile plug formation and bile duct paucity. Ursodeoxycholic acid (UDCA), a widely used ...

Degree of benefit with UDCA is uncertain. Aim: To Look at Mode of diagnosis for CFALD and Effectiveness & safety of UDCA in our unit. Methods: Retrospective review on all patients currently ...

Ursodeoxycholic acid (UDCA) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies of diverse etiologies and has been mainly used as a supportive treatment in ...

The ground-breaking study, led by researchers at the University of Sheffield in partnership with Sheffield Teaching Hospitals NHS Foundation Trust, is assessing the safety and tolerability of the ...

That leaves patients with limited second-line options for treatment if they fail to respond to or cannot tolerate ursodeoxycholic acid (UDCA), the standard first-line therapy, according to the ...

The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in adults, either in combination with ursodeoxycholic acid (UDCA) or as monotherapy for those ...